IMRÉ Corp. deal

As amended, IMRE eliminated the purchase minimums and the take-or-pay concept of the original agreement. Baxter also is free to pursue competing therapies for the immune-related bleeding disorder. In return, Baxter paid its $3 million take-or-pay commitment due March 31, and will buy $1 million of Prosorba columns in the second quarter. Baxter also will assume responsibility for sales and marketing support for the ex vivo immunoadsorption technology, which IMRE said will save it $1 million over the next two years. ...